SNORD13: A Protein Exploring Potential as A Drug Target Or Biomarker

Target Name: SNORD13

NCBI ID: G692084

SNORD13

Other Name(s): SNORD13A | RNU13 | U13 | Small nucleolar RNA, C/D box 13 | small nucleolar RNA, C/D box 13

SNORD13: A Protein Exploring Potential as A Drug Target Or Biomarker

SNORD13 (SNORD13A) is a protein that is expressed in the brain and is known for its role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. The study of SNORD13A and its potential as a drug target or biomarker has gained significant attention in recent years.

Synaptic plasticity is a critical aspect of brain development and function. During development, the brain is able to adapt and change in order to accommodate new experiences and environments. This process is thought to be closely related to the regulation of neurotransmitter release, which is the ability of the brain to communicate with its neighbors, such as the ability to learn and remember.

SNORD13A has been shown to play a crucial role in the regulation of neurotransmitter release. The protein is known to interact with a variety of different neurotransmitters, including dopamine, a chemical that is involved in motivation and pleasure.

One of the key functions of SNORD13A is its role in the regulation of dopamine release. Studies have shown that SNORD13A plays a role in the regulation of dopamine release from the prefrontal cortex, which is the part of the brain that is responsible for decision-making and planning.

In addition to its role in dopamine release, SNORD13A has also been shown to play a role in the regulation of other neurotransmitters, including GABA, a chemical that is involved in anxiety and stress.

The potential implications of SNORD13A as a drug target or biomarker are significant. If SNORD13A is found to be involved in the regulation of neurotransmitter release, it could be a target for drugs that are designed to modulate neurotransmitter levels. This could be useful for the treatment of a variety of neurological and psychiatric disorders, including anxiety, depression, and addiction.

In addition to its potential as a drug target, SNORD13A has also been shown to be a potential biomarker for a variety of neurological disorders. The protein has been shown to be expressed in the brains of individuals with a variety of different neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. This suggests that SNORD13A may be a useful biomarker for these disorders.

Overall, the study of SNORD13A and its potential as a drug target or biomarker continues to attract significant attention. The protein's role in the regulation of neurotransmitter release and its potential as a target for drugs and biomarkers makes it an important area of 鈥嬧?媟esearch for the study of brain function and the development of new treatments for neurological and psychiatric disorders.

Protein Name: Small Nucleolar RNA, C/D Box 13

The "SNORD13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets